Outlook Therapeutics Investor Relations Material
Latest events
Study Update
Outlook Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Outlook Therapeutics Inc
Access all reports
Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and launching innovative treatments for ocular diseases. The company is currently working on ONS-5010 / LYTENAVA™ (bevacizumab-vikg), aiming to make it the first FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). The company is headquartered in Iselin, New Jersey, and its shares are listed on the Nasdaq.
Latest articles
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
Ticker symbol
OTLK
Country
🇺🇸 United States